Patient selection for oncology phase I trials: A multi-institutional study of prognostic factors

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 996-1004

  Olmos, David ^a,b   A'Hern, Roger P ^b   Marsoni, Silvia ^f   Morales, Rafael ^h   Gomez Roca, Carlos ⁱ   Verweij, Jaap ^k   Voest, Emile E ^l   Schof̈fski, Patrick ⁿ   Ang, Joo Ern ^b   Penel, Nicolas ^j   Schellens, Jan H ^m   Del Conte, Gianluca ^g   Brunetto, Andre T ^a   Evans, T R Jeffry ^c   Wilson, Richard ^d   Gallerani, Elisa ^o   Plummer, Ruth ^e   Tabernero, Josep ^h   Soria, Jean Charles ⁱ   Kaye, Stan B ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e FREEMAN HOSPITAL   (United Kingdom)

^f Southern Europe New Drug Organization Foundation   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j CENTRE OSCAR LAMBRET   (France)

^k ERASMUS MEDICAL CENTER   (Netherlands)

^l UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^m NETHERLANDS CANCER INSTITUTE   (Netherlands)

ⁿ UNIVERSITY OF LEUVEN   (Belgium)

^o REGIONAL HOSPITAL OF LUGANO   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; DATA BASE; DISEASE COURSE; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONCOLOGY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TUMOR GROWTH; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE I AS TOPIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; PATIENT SELECTION; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; YOUNG ADULT;

EID: 84857055503     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.5074     Document Type: Article

References (22)

1. Verweij J: 'No risk, no fun': Challenges for the oncology phase I clinical trial time-performance. Eur J Cancer 44:2600-2607, 2008
2. Eisenhauer EA, O'Dwyer PJ, Christian M, et al: Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684-692, 2000 (Pubitemid 30078550)
3. Arkenau HT, Olmos D, Ang JE, et al: Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital experience. Br J Cancer 98:1029-1033, 2008 (Pubitemid 351399798)
4. Dowlati A, Manda S, Gibbons J, et al: Multi-institutional phase I trials of anticancer agents. J Clin Oncol 26:1926-1931, 2008
5. Nurgat ZA, Craig W, Campbell NC, et al: Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92:1001-1005, 2005 (Pubitemid 40546660)
6. Arkenau HT, Barriuso J, Olmos D, et al: Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 27:2692-2696, 2009
7. Arkenau HT, Olmos D, Ang JE, et al: 90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? Eur J Cancer 44:1536-1540, 2008
8. Bachelot T, Ray-Coquard I, Catimel G, et al: Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 11:151-156, 2000 (Pubitemid 30148727)
9. Han C, Braybrooke JP, Deplanque G, et al: Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 89:1166-1171, 2003 (Pubitemid 37363397)
10. Italiano A, Massard C, Bahleda R, et al: Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 19:787-792, 2008 (Pubitemid 351467383)
11. Janisch L, Mick R, Schilsky RL, et al: Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 74:1965-1973, 1994 (Pubitemid 24301862)
12. Olmos D, Baird RD, Yap TA, et al: Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res 17:5188-5196, 2011
13. Penel N, Delord JP, Bonneterre ME, et al: Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. Invest New Drugs 28:76-82, 2010
14. Penel N, Vanseymortier M, Bonneterre ME, et al: Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 26:53-58, 2008
15. Wheler J, Tsimberidou AM, Hong D, et al: Survival of patients in a Phase 1 Clinic: The M. D. Anderson Cancer Center experience. Cancer 115:1091-1099, 2009
16. Yamamoto N, Tamura T, Fukuoka M, et al: Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 15:737-741, 1999
17. Brunetto AT, Ang JE, Olmos D, et al: A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: Unplanned admissions as an early indicator of patient attrition. Eur J Cancer 46:2739-2745, 2010
18. Ang JE, Olmos D, Moreno Garcia V, et al: Utility of novel dynamic clinical indices in patients (pts) enrolled in a phase I (Ph I) oncology trial as markers of prognosis and treatment benefit. J Clin Oncol 29:178s, 2011 (suppl; abstr 2555)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Horstmann E, McCabe MS, Grochow L, et al: Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895-904, 2005 (Pubitemid 40300298)
21. Roberts TG Jr, Goulart BH, Squitieri L, et al: Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130-2140, 2004 (Pubitemid 39435104)
22. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al: Pilot study using molecular profiling of patients'tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877-4883, 2010